Certainly, the change in the media mix is valid. Of the 2,904 commercial messages that consumers receive each day, they pay attention to only 52, according to a study conducted by ad agency Carat in 2003.
However, though consumers may be viewing fewer commercials, they're still watching TV and absorbing information. To that end, companies don't have to do away with television as a marketing platform completely. Instead, pharma companies should think about embracing new longer-form content options, targeted TV channels, and creative on-demand alternatives that are likely to attract the segment of audience they're after.Health Condition, by Channel
But the patients who are searching for disease information are increasingly taking the attitude of "my health, my disease, my media." These health-hungry consumers want easier access to the information that will help them better their lives. They don't want scheduled media; they want to control their TV programming just as they control their TiVos and iPods.
Certainly, disease-specific web streams and broadcast options are beginning to emerge, providing pharma a vehicle to engage specific types of patients when and where they want to be reached. Until recently, these health condition programs aired primarily in hospital waiting rooms or patient rooms, and were used to help educate patients on their illness for a faster recovery.
But now, consumers from households with cable or satellite television can access various health-related programs, like Medical Breakthroughs, airing on network affiliates in major markets, to prevent disease and hospitalization in the first place.
DLife informs patients about new therapies, testing devices, research, and tips on compliance—picking up where many healthcare professionals leave off in offering knowledge and motivation to keep patients persistent and compliant with their drug regimens. The content is educational in nature, offering, for example, tips on how diabetics can overcome their fear of needles or an explanation of how insulin works. Because it is focused on a specific disease state, the audience that tunes in represents exactly whom companies want to reach—those who are eager to learn about therapy options for the specified disease or other co-morbid conditions likely to affect the patient.